About the Connective Tissue Disease - Interstitial Lung Disease (CTD-ILD) Working Group

Interstitial lung diseases (ILD), including those related to connective tissue disease (CTD), and idiopathic pulmonary fibrosis (IPF) carry high morbidity and mortality.

Great efforts are under way to develop and investigate meaningful treatments in the context of clinical trials. However, efforts have been challenged by a lack of validated outcome measures and by inconsistent use of measures in clinical trials.

Khanna Headshot

Dinesh Khanna

Co-Chair

Montesi_Picture

Sydney Montesi

Co-Chair

 

susanna proudman

Susanna Proudman

Co-Chair

Simon Walsh

Co-Chair

Athol Wells

Co-Chair

OMERACT Endorsed Core Domain Set Clinical Trials in Connective Tissue Disease - Interstitial Lung Disease (CTD-ILD)

OMERACT Onions with Instruments

OMERACT INSTRUMENT SELECTION CERTIFICATES

Working Group Publications

Outcome measurement instrument selection for lung physiology in systemic sclerosis-associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process

Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) — Report from OMERACT CTD-ILD Working Group

Reconciling Healthcare Professional and Patient Perspectives in the Development of Disease Activity and Response Criteria in Connective Tissue Disease–related Interstitial Lung Diseases

Developing Disease Activity and Response Criteria in Connective Tissue Disease-related Interstitial Lung Disease 

Scroll to Top